Does Histologic Subtype Affect Oncologic Outcomes After Nephron-sparing Surgery?

Maxime Crépel, Hendrik Isbarn, Umberto Capitanio, Daniel Liberman, Claudio Jeldres, Maxine Sun, Shahrokh F. Shariat, Hugues Widmer, Philippe Arjane, Markus Graefen, Francesco Montorsi, Jean Jacques Patard, Paul Perrotte, Pierre I. Karakiewicz

Research output: Contribution to journalArticlepeer-review


Objectives: To test whether renal cell carcinoma (RCC) histologic subtypes (HSs) affect cancer-specific mortality after nephron-sparing surgery (NSS). HSs are considered of prognostic value in RCC. For example, the papillary HS might confer a worse prognosis, and, at some centers, only radical nephrectomy is performed for the papillary HS. Methods: We used univariate and multivariate Cox regression models to study patients with Stage T1N0M0 RCC treated with NSS (n = 1205) from 1988 to 2004. The data were taken from 9 Surveillance, Epidemiology, and End Results registries. Results: At 36 months after NSS, the cancer-specific mortality rate was 97.8%, 100%, and 97.4% for a clear cell, chromophobe, and papillary RCC HS, respectively. On univariate and multivariate analyses, no statistically significant differences were recorded with regard to the HS. Conclusions: Despite the suggested more aggressive phenotype of the papillary HS, we found no difference among the papillary, chromophobe, and clear cell variants. Thus, the diagnosis of one HS vs another HS should not deter from the use of NSS when cancer-specific mortality is considered as an endpoint. Crown

Original languageEnglish
Pages (from-to)842-845
Number of pages4
Issue number4
Publication statusPublished - Oct 2009

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Does Histologic Subtype Affect Oncologic Outcomes After Nephron-sparing Surgery?'. Together they form a unique fingerprint.

Cite this